Disitamab Vedotin vs Trastuzumab pamirtecan

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

HER2-Positive Breast Cancer

Shared mechanism: HER2 · full HER2-Positive Breast Cancer pipeline

Disitamab Vedotin

Marketed by RemeGen Co., Ltd. and partners

Phase 2/3 in HER2-Positive Breast Cancerantibody-drug conjugate
Partial signal

NCT03500380 · Phase 2/3 · status unknown

This trial randomized 301 patients with HER2-positive metastatic breast cancer to disitamab vedotin or an active comparator regimen (lapatinib plus capecitabine), with tumor progression independently reviewed to reduce bias, but treatment assignment was not blinded. Registry results were not posted at the time of grading; the key result shown was recovered from the cited external source.

Caveat: this result is taken from a company announcement or a news report of one, not from the trial registry or a peer-reviewed publication. Treat the figures as the sponsor's own statement, not as independently verified evidence.

Next expected readout: January 2028 · NCT07366840 (registry estimate)

Reported efficacy

Progression-free Survival (PFS) as Assessed by an IRC (From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 24 months): Median progression-free survival assessed by blinded independent review committee (phase 3 stage, 104 patients randomized): 9.9 months with disitamab vedotin versus 4.9 months with lapatinib plus capecitabine; stratified hazard ratio 0.56 (95.48% CI: 0.35-0.91). (met)

Result source: NCT03500380

Trastuzumab pamirtecan

Developed by BioNTech under a licence from DualityBio Inc.

Phase 3 in HER2-Positive Breast Cancerantibody-drug conjugate
Partial signal

NCT06265428 · Phase 3 · active, not recruiting

Patients were randomly assigned to DB-1303/BNT323 or the active comparator T-DM1 in a Phase 3 trial of about 228 patients, with disease progression (PFS) as the primary measure -- a hard clinical endpoint. However, the study is open-label with no blinding of patients or investigators, and while outside reporting indicates the drug beat T-DM1 on PFS at an interim look, no specific numbers (hazard ratio, medians, or p-value) are available to verify the strength of that result, so this is graded as solid but not top-tier evidence.

Caveat: this result is taken from a company announcement or a news report of one, not from the trial registry or a peer-reviewed publication. Treat the figures as the sponsor's own statement, not as independently verified evidence.

Next expected readout: December 2027 · NCT06265428 (registry estimate)

Reported efficacy

Progression Free Survival (PFS) by Blinded Independent Central Review (BICR) assessment per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) (Up to approximately 24 months.): NCT06265428, primary endpoint progression-free survival: BNT323/DB-1303 (trastuzumab pamirtecan) vs T-DM1 met the primary PFS endpoint at a pre-specified interim analysis. (met)

Result source: NCT06265428

Results for HER2-Positive Breast Cancer

There are not yet structured results for two selected drugs in this indication. Available results are listed below instead of an empty comparison table.

Reviewed results are available, but are not yet structured for this comparison. These sourced summaries are shown separately from the aligned rows.

Disitamab Vedotin
Median progression-free survival assessed by blinded independent review committee (phase 3 stage, 104 patients randomized): 9.9 months with disitamab vedotin versus 4.9 months with lapatinib plus capecitabine; stratified hazard ratio 0.56 (95.48% CI: 0.35-0.91). NCT03500380 · Phase 2/3 · design grade: moderate · publication or press release
Trastuzumab pamirtecan
NCT06265428, primary endpoint progression-free survival: BNT323/DB-1303 (trastuzumab pamirtecan) vs T-DM1 met the primary PFS endpoint at a pre-specified interim analysis. NCT06265428 · Phase 3 · design grade: moderate · publication or press release

HR+/HER2- Metastatic Breast Cancer

Shared mechanism: HER2 · full HR+/HER2- Metastatic Breast Cancer pipeline

Disitamab Vedotin

Marketed by RemeGen Co., Ltd. and partners

Phase 3 in HR+/HER2- Metastatic Breast Cancerantibody-drug conjugate
Partial signal

NCT04400695 · Phase 3 · recruiting

This trial randomized 366 patients with HER2-low breast cancer to disitamab vedotin or one of several standard chemotherapy options chosen by their physician, with tumor progression independently reviewed to reduce bias, but treatment assignment was not blinded. Results have not yet been posted to the registry.

Next expected readout: December 2026 · NCT05831878 (registry estimate)

Reported efficacy

RP2D (Estimated 2 year): Confirmed ORR at 2.0 mg/kg Q2W: 42.9% (9/21) in HER2-overexpression and 33.3% (22/66) in HER2-low advanced breast cancer; median PFS 5.7 and 5.1 months (not_applicable)

Result source: NCT03052634

Trastuzumab pamirtecan

Developed by BioNTech under a licence from DualityBio Inc.

Phase 3 in HR+/HER2- Metastatic Breast Cancerantibody-drug conjugate
not yet graded

No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.

Next expected readout: August 2029 · NCT06827236 (registry estimate)

No aligned efficacy figure on record for this race.

Results for HR+/HER2- Metastatic Breast Cancer

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointDisitamab VedotinTrastuzumab pamirtecan
PFS, median—Trial running · NCT05904964—Trial running · NCT06018337
OS, median—Trial running · NCT05904964—Trial running · NCT06018337
ORR—Trial running · NCT05904964—Trial running · NCT06018337
Clinical benefit rate—Trial running · NCT05904964—Trial running · NCT06018337

PFS, median

Disitamab Vedotin
—Trial running · NCT05904964
Trastuzumab pamirtecan
—Trial running · NCT06018337

OS, median

Disitamab Vedotin
—Trial running · NCT05904964
Trastuzumab pamirtecan
—Trial running · NCT06018337

ORR

Disitamab Vedotin
—Trial running · NCT05904964
Trastuzumab pamirtecan
—Trial running · NCT06018337

Clinical benefit rate

Disitamab Vedotin
—Trial running · NCT05904964
Trastuzumab pamirtecan
—Trial running · NCT06018337
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

Trastuzumab pamirtecan: no structured comparison results are available for HR+/HER2- Metastatic Breast Cancer.

Reviewed results are available, but are not yet structured for this comparison. These sourced summaries are shown separately from the aligned rows.

Disitamab Vedotin
Confirmed ORR at 2.0 mg/kg Q2W: 42.9% (9/21) in HER2-overexpression and 33.3% (22/66) in HER2-low advanced breast cancer; median PFS 5.7 and 5.1 months NCT03052634 · Phase 1/2 · design grade: weak · publication or press release

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Disitamab Vedotin's landscape · Trastuzumab pamirtecan's landscape